Physician profile
Thy Dinh
NPI 1033632344
$2,225.01
in general payments reported to CMS, 2019-2025
9 companies · $740 in 2025
The $740 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $126 · 2021: $79.94 · 2022: $496 · 2023: $165 · 2024: $400 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $904.66 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $667.63 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $194.38 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $146.58 | 2023 | Tepezza |
| Alcon Vision LLC | $93.05 | 2019 | |
| Biotissue Holdings INC. | $79.99 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $56.20 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $42.36 | 2023-2024 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator |
| Sun Pharmaceutical Industries INC. | $40.16 | 2022-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thy Dinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.